Navigation Links
Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures : Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers
Date:10/15/2008

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that Grupo IMO of Madrid, Spain, recently hosted a symposium on the clinical use of the HiArt treatment system for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Symposium speakers highlighted the HiArt system’s inherent suitability for stereotactic procedures with respect to dose conformality and homogeneity; presented clinical work on a variety of intra- and extracranial cases; and discussed future research goals.

MADISON, Wis. (Business Wire EON) October 15, 2008 -- According to Jef Van Dam, TomoTherapy EMEA General Manager: "We are extremely pleased that Grupo IMO hosted this symposium highlighting the excellent clinical stereotactic work being done by TomoTherapy customers. We are eager to demonstrate how the clinical applications of TomoTherapy continue to grow as new treatment possibilities are explored by our clinical partners."

The 'Symposium on Tomo-Radiosurgery' included presentations from Dr. Jos Sambls, neurosurgeon and Grupo IMO president, Dr. Jos Miguel Delgado, clinical physicist and technical director for Grupo IMO, and Dr. Matthias Uhl, radiation oncologist, Heidelberg University Clinic, Heidelberg, Germany. The event was held in conjunction with the Spanish Radiosurgery Conference.

Peter Hoban, Ph.D., TomoTherapy senior product managerand medical physicist, began the program by outlining features that make the HiArt system ideal for providing stereotactic treatments: "TomoTherapy's integrated imaging and delivery platform allows one simple process to be used for both stereotactic and intensity-modulated radiation therapy (IMRT) treatments. The system clearly lends itself to a diverse range of clinical indications, as evidenced by the presentations of Drs. Sambls, Delgado and Uhl."

  • Sambls and Dr. Delgado presented technical and clinical stereotactic work using the TomoTherapy HiArt treatment system and discussed Grupo IMO's research goals for the future.

Said Dr. Sambls: "TomoTherapy HiArt allows the development of new techniques for treating brain tumors with maximum precision. In this sense, we have achieved great preliminary results with what we call Tomo-Radiosurgery, fundamentally with regard to irregularly shaped brain tumors, brain metastases and tumors located close to critical organs such as the optic nerves and the brain stem. Another example is the treatment of acoustic neurinoma. We believe TomoTherapy's especially homogenous dose distribution capabilities may help to spare sensitive auditory nerve tissue."

  • Matthias Uhl explained how University Clinic Heidelberg has expanded its own use of the TomoTherapy HiArt system to include stereotactic treatments.

"We are applying TomoTherapy to SBRT for early-stage lung cancer and also multiple metastases in the brain and liver," said Dr. Uhl. "Treating multiple lesions simultaneously results in a reduced amount of timethe patient spends in the treatment room compared with conventional treatment alternatives."

About Grupo IMO

Grupo IMO is the first facility in Spain to offer TomoTherapy radiation treatments. More than 300 patients have been treated on the TomoTherapy HiArt System since April 2006. Established in 1991, Grupo IMO has the largest autonomous network of ten reference centers for cancer treatment using radiotherapy and radiosurgery techniques in Spain.

About TomoTherapy Incorporated

TomoTherapy Incorporated has developed, markets and sells the TomoTherapy HiArt treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The HiArt treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

2008 TomoTherapy Incorporated. All rights reserved.TomoTherapy, the TomoTherapy logo and HiArt are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated.

Read the full story at http://www.prweb.com/releases/grupo_imo/stereotactic_body/prweb1480034.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively
2. Grupo Casa Saba Announces Fourth Quarter 2007 Results
3. Grupo Casa Saba Announces Third Quarter 2007 Results
4. Pennsylvania Breast Cancer Coalition Hosts Annual Conference
5. Baird Hosts Small Cap Health Care Conference : Senior Healthcare Distribution & Services Research Analyst Eric Coldwell Shares Insights on Sector
6. Health Insurance Industry Hosts Roundtable Discussion on Health Care Reform in Albuquerque
7. RMA of Michigan Hosts 1st Metro Detroit Area Hope Uncorked: Exclusive Wine Tasting Event To Benefit Fertile Hope
8. Alameda County Hosts National Initiative to Reduce Health Disparities
9. Hospira Hosts Conference Call for Second-Quarter 2008 Earnings
10. National Medical Association Hosts the 2008 Annual Convention and Scientific Assembly
11. Bioniche Hosts Veterinarians and Food Industry Reps at Two-Day E. coli O157:H7 Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Grupo IMO Hosts Symposium on Use of TomoTherapy for Stereotactic Radiosurgery and Stereotactic Body Radiation Procedures :  Experts Detail HiArt Platform Advantages for Treatment of Brain, Lung, Pancreatic and Metastatic Cancers 
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating ... many ways they remain in the eye of the beholder, according to experts who ... of The American Journal of Managed Care. For the full issue, click here ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
Breaking Medicine Technology: